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Purpose: To examine if the gene encoding C-reactive protein (CRP), a biomarker of inflammation, confers risk for
neovascular age-related macular degeneration (AMD) in the presence of other modifiers of inflammation, including body
mass index (BMI), diabetes, smoking, and complement factor H (CFH) Y402 genotype. Additionally we examined the
degree to which CRP common variation was in linkage disequilibrium (LD) within our cohort.
Methods: We ascertained 244 individuals from 104 families where at least one member had neovascular AMD, and a
sibling had normal maculae and was past the age of the index patient’s diagnosis of neovascular AMD. We employed a
direct sequencing approach to analyze the 5′-promoter region as well as the entire coding region and the 3′-untranslated
region of the CRP gene. CFH Y402 genotype data was available for all participants. Lifestyle and medical factors were
obtained via administration of a standardized questionnaire. The family-based association test, haplotype analysis,
McNemar’s test, and conditional logistic regression were used to determine significant associations and interactions.
Haploview was used to calculate the degree of LD (r2) between all CRP variants identified.
Results:  Six  single  nucleotide  polymorphisms  (SNPs;  rs3091244,  rs1417938,  rs1800947,  rs1130864,  rs1205,  and
rs3093068) comprised one haplotype block of which only rs1130864 and rs1417938 were in high LD (r2=0.94). SNP
rs3093068 was in LD but less so with rs3093059 (r2=0.83), which is not part of the haplotype block. Six SNPs made up
six different haplotypes with ≥ 5% frequency, none of which were significantly associated with AMD risk. No statistically
significant association was detected between any of the nine common variants in CRP and neovascular AMD when
considering disease status alone or when controlling for smoking exposure, BMI, diabetes, or CFH genotype. Significant
interactions were not found between CRP genotypes and any of the risk factors studied. No novel CRP variation was
identified.
Conclusions: We provide evidence that if elevated serum/plasma levels of CRP are associated with neovascular AMD,
it is likely not due to genetic variation within CRP, but likely due to variations in some other genetic as well as
epidemiological factors.
The advanced stages of age-related macular degeneration
(AMD) are responsible for the majority of visual loss observed
in  the  developed  world.  In  the  United  States,  about  1.75
million people over the age of 50 years have advanced AMD,
mostly in the form of neovascular AMD, in at least one eye,
and it is predicted that this number will increase to 2.95 million
individuals by 2020 [1]. The initial or acute phase response of
the immune system to infection or other stressors involves the
release of cytokines such as C-reactive protein (CRP) [2,3].
Measurement  of  such  inflammatory  markers  in  serum  or
plasma has been shown to predict risk of advanced forms of
AMD [4,5], lending support to the hypothesis that AMD may
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be  in  part  be  a  chronic  inflammatory  systemic  disease.
However, prospective studies from the Cardiovascular Health
Study and Beaver Dam Eye Study concluded that circulating
levels  of  CRP  were  not  associated  with  either  early  or
advanced AMD [6,7]. Identifying biomarkers that may predict
risk  of  the  more  advanced  stages  of  AMD  may  point  to
pharmacological targets relevant to preventing or delaying
progression of disease. Therefore it is important that it be
definitively determined if CRP is a valuable biomarker or
prognostic  tool  for  AMD  risk.  Evidence  for  the  role  of
inflammation  in  AMD  also  comes  from  genetic  studies
showing that the most consistently reported genetic risk factor
for both early and advanced forms of AMD is the Y402H
disease-associated variant in the complement factor H gene
(CFH) [8-12]. Moreover, this disease-associated variant is
located in a binding site for CRP, and serum from AMD
patients homozygous for CFH 402H were shown to have
decreased binding to the CRP protein [13].
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1487It  is  well  established  that  common  genetic  variation
within  CRP  are  encompassed  by  seven  single  nucleotide
polymorphisms  (SNPs)  that  have  been  associated  with
circulating CRP levels [14-21], but it is unclear whether these
common variations in CRP are associated with AMD risk.
Lack of agreement exists between the two studies conducted
to date on CRP variation and AMD risk. Specifically, data
from  the  Netherlands  demonstrated  that  CRP  haplotypes
associated  with  higher  circulating  CRP  levels  increase  or
decrease  AMD  risk  depending  on  an  individual’s  CFH
Y402H genotype [22]. However, data from the Physicians
Health Study did not find an association between common
genetic  variation  in  CRP  and  risk  of  AMD  even  when
controlling for CFH 402H genotype [23]. Common variation
was defined differently between these two studies and may
partly explain the difference in findings
Therefore, we employed a direct sequencing approach to
encompass both sets of SNPs previously evaluated for their
association with AMD risk [22,23] and also uncover any novel
variation that could be associated with AMD risk within the
CRP gene. Our study design also included controlling for
factors that could modify CRP expression as well as risk of
AMD, including CFH genotype, smoking, body mass index
(BMI), and diabetes, reducing the likelihood of observing
false positive correlations. Our study population consisted of
244 individuals from 104 families [1,24]. The affected or
index patient was in the upper 10% of disease severity and the
other member, the unaffected sibling, was in the bottom 10%–
30% of disease severity (AREDS category one or less). We
have previously demonstrated that such types of sib pairs can
be powerful in identifying the contribution that many genetic
variants, even those with a modest effect, along with smoking
make simultaneously to AMD susceptibility [25,26].
Mathematical analyses indicate that the evaluation of sib
pairs who are extremely discordant for a multifactorial trait
can  be  the  most  informative  for  identifying  the  genetic
variants  that  govern  the  trait  and  may  be  40  times  more
powerful than case-controls study designs [27,28].
METHODS
Patient population: The protocol was reviewed and approved
by the Institutional Review Boards at the Massachusetts Eye
and Ear Infirmary, Boston, Massachusetts and the William
Beaumont Hospital, Royal Oak, Michigan, and it conformed
to the tenets of the Declaration of Helsinki. Eligible patients
were enrolled in this study after they gave informed consent
either in person, over the phone, or through the mail, before
answering  questions  to  a  standardized  questionnaire  and
donating 10 to 50 ml of venous blood.
Details of the recruitment of patients and their siblings
are described elsewhere [25,29]. In brief, we recruited 244
individuals comprising 104 extremely discordant sib pairs, all
all of Northern European descent and 50 years of age or older.
All index patients had the neovascular form of AMD in at least
one  eye,  defined  by  subretinal  hemorrhage,  fibrosis,  or
fluorescein  angiographic  presence  of  neovascularization
documented at the time of, or before, enrollment in the study.
Patients whose only exudative finding was a retinal pigment
epithelium detachment were excluded because this finding
may not represent definite neovascular AMD and, therefore,
the severe phenotype we sought. Also excluded were patients
with  signs  of  pathologic  myopia,  presumed  ocular
histoplasmosis syndrome, angioid streaks, choroidal rupture,
any hereditary retinal diseases other than AMD, and previous
laser treatment due to retinal conditions other than AMD.
Figure 1. Schematic of the C-reactive protein gene representing the
promoter region, the 2 exons, and the 3′ untranslated region. The
coding  regions  of  the  exons  are  colored  dark.  The  untranslated
regions are depicted in the lighter color. All nine single nucleotide
polymorphisms (SNPs) were genotyped by direct sequencing except
for  rs3093068  which  was  genotyped  using  the  Sequenom
technology. The asterisks represent the 7 SNPs that define common
variation in CRP. Please note that 3 of these SNPs are located several
base pairs upstream from the ATG start site. Although we sequenced
92.3% of the CRP gene, no novel variation was found.
TABLE 1. PRIMERS USED
Location Forward primer Reverse primer
5′-UTR/promoter TTTACTGTCAGGGCCGTCAT TCTCTCAGGGCTCCACTTTG
Exon 1, Intron 1 TCTTCCCGAAGCTCTGACAC ACACACACCATGAAGGATGC
Exon 2 (part 1) GTGTAACTGGAGAAGGGGTCA CTTCTGCCCCCACAGTGTAT
Exon 2 (part 2) TACAGTGGGTGG GTCTGAAA TGGGAACCATGCAGTGTAAA
3′-UTR GCCCTTCAGTCCTAATGTCC AGATCAGCGCTTCCTTCTCA
3′ UTR TGGTTTTTG TTTGCTTGCAG TGGGCAGTCCAGGTGTAGAT
All primers are written in the 5′-3′ direction.
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1488The unaffected siblings had normal maculae at an age
older than that at which the index patient was first diagnosed
with neovascular AMD. Maculae were defined as the zone
centered at the foveola and extending 2 disc diameters (3000
microns) in radius. Normal maculae fulfilled the following
criteria:  0–5  small  drusen  (all  less  than  63  microns  in
diameter), no pigment abnormalities, no geographic atrophy,
and  no  neovascularization  (as  defined  previously  [26,29];
AMD “category 1” or less on the AREDS scale). Disease
status of every participant was confirmed by at least two of
the  investigators  by  evaluation  of  fundus  photographs  or
fluorescein angiograms except when one of the investigators
directly examined an unaffected sibling during a home visit
(n=4 cases).
Additionally,  we  administered  a  standardized
questionnaire to all eligible participants in person or over the
phone to ascertain smoking exposure measured in pack years,
BMI, and history of diabetes. We used the date of the index
patient’s fundus photographs as our cutoff date for smoking
exposure for both members in a sibship. In most cases, the
diagnosis  of  AMD  was  made  simultaneously  with  the
diagnosis of neovascular AMD.
Genotyping: For all molecular procedures leukocyte DNA
was either purified by using standard phenol-chloroform or
DNAzol (Invitrogen Corporation, Carlsbad, CA) extraction
protocols. Oligonucleotide primers were selected using the
Primer3 program to encompass the promoter, both exons,
including splice sites and the 3′-UTR of CRP. Primer pairs
were  designed  according  to  the  CRP  gene  sequence  in
Ensembl and can be seen in Table 1. The fragments analyzed
included the set of established common CRP SNPs (Figure 1
and Table 2). For all amplicons, polymerase chain reaction
(PCR) was used to amplify genomic DNA fragments from 20
ng  of  leukocyte  DNA  in  a  solution  of  10×  PCR  buffer
containing 25 mM of MgCl2, 0.2 mM each of dATP, dTTP,
dGTP, and dCTP, and 0.5 units of Taq DNA polymerase (USB
Corporation, Cleveland, OH). Next, 5M betaine was added to
each PCR resulting in a final concentration of 1.5M (Sigma-
Aldrich, St. Louis, MO). The temperatures used during the
polymerase chain reaction were as follows: 95 °C for 5 min
followed by 35 cycles of 58 °C for 30 s, 72 °C for 30 s, and
95 °C for 30 s, with a final annealing at 58 °C for 1.5 min and
extension of 72 °C for 5 min. For sequencing reactions, PCR
products were digested according to manufacturer’s protocol
with ExoSAP-IT (USB Corporation) then were subjected to a
cycle sequencing reaction using the Big Dye Terminator v3.1
Cycle Sequencing kit (Applied Biosystems, Foster City, CA)
according  to  the  manufacturer’s  protocol.  Products  were
purified  with  Performa  DTR  Ultra  96-well  plates  (Edge
Biosystems,  Gaithersburg,  MD)  to  remove  excess  dye
terminators. Samples were sequenced on an ABI Prism 3100
DNA sequencer (Applied Biosystems). Electropherograms
generated from the ABI Prism 3100 were analyzed using the
Lasergene  DNA  and  protein  analysis  software  (DNAStar,
Inc., Madison, WI). Electropherograms were read by two
independent evaluators without knowledge of the subject’s
TABLE 2. RESULTS OF SINGLE MARKER ANALYSIS FROM THE FAMILY-BASED ASSOCIATION TEST, ASSUMING AN ADDITIVE GENETIC MODEL
SNP
Number of
informative
families
Variance
      (S) Z value p value
rs3093059† 15 3.604 1.010 0.31
rs2794521† 41 11.408 0.197 0.84
rs3093062 2 ***** ***** *****
rs3091244† 42 13.580 1.123 0.26
rs1417938† 46 12.718 0.365 0.72
rs1800947† 9 3.075 0.855 0.39
rs1130864† 45 12.546 0.885 0.38
rs1205† 46 16.403 0.593 0.55
rs3093068* 12 3.00 0.577 0.564
Results of Family-Based Association Test (FBAT) assuming an additive genetic model. All nine genotyped single nucleotide
polymorphisms  (SNPs) are shown, including those seven that represent common genetic variation within CRP (as indicated by
†). SNPs that had less than 4 informative families (as indicated by *****) could not be analyzed. Results shown are based on
101 families, using one pair per family.
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1489disease  status.  All  patient  DNAs  were  sequenced  in  the
forward direction (5′ to 3′), unless variants or polymorphisms
were identified, in which case confirmation was obtained in
some cases by sequencing on the reverse strand.
So  that  appropriate  inferences  between  common
variation in CRP and AMD risk could be made, we analyzed
the 3′-UTR SNP that was part of the previously reported
significantly associated AMD risk haplotype [22] using the
Sequenom  technology  (Sequenom,  Inc.,  San  Diego,  CA).
PCR  primers  were  designed  by  the  Sequenom  Spectro
Designer software (version 3.0.0.3) by inputting sequence
containing the SNP site and 100 bp of flanking sequence on
either side of the SNP. Briefly, 10 ng genomic DNA were
amplified in a 5 μl reaction containing 1X HotStar Taq PCR
buffer (Qiagen), 1.625 mM MgCl2, 500 μM each dNTP, 100
nM  each  PCR  primer,  0.5  U  HotStar  Taq  (Qiagen).  The
reaction was incubated at 94 °C for 15 min followed by 45
cycles of 94 °C for 20 s, 56 °C for 30 s, 72 °C for 1 min,
followed by 3 min at 72 °C. Excess dNTPs were then removed
from the reaction by incubation with 0.3 U shrimp alkaline
phosphatase (USB) at 37 °C for 40 min followed by 5 min at
85 °C to deactivate the enzyme. Single primer extension over
the SNP was performed in a final concentration of between
0.625 μM and 1.5 μM for each extension primer (depending
on  the  mass  of  the  probe),  iPLEX  termination  mix
(Sequenom)  and  1.35  U  iPLEX  enzyme  (Sequenom)  and
cycled using a two-step 200 short cycles program; 94 °C for
30 s followed by 40 cycles of 94 °C for 5 s, 5 cycles of 52 °C
TABLE 3. SINGLE FACTOR CONDITIONAL LOGISTIC REGRESSION ANALYSES OF RISK FACTORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Variable Risk Factor Referent O.R. (95% C.I.) p value
SNP rs3093059* CT or CC TT 0.48 (0.16–1.46) 0.20
SNP rs2794521* GA or GG AA 1.02 (0.52–2.00) 0.95
SNP rs3093062 AG or AA GG 1.23 (0.06–26.00) 0.90
SNP rs3091244*
CT, TT, CA,
TA or AA CC 0.74 (0.35–1.55) 0.42
SNP rs1417938* TA or TT AA 0.91 (0.46–1.80) 0. 78
SNP rs1800947* CG or CC GG 0.64 (0.17–2.43) 0. 51
SNP rs1130864* TC or TT CC 0.72 (0.36–1.45) 0.35
SNP rs1205* AG or AA GG 1.24 (0.64–2.42) 0.53
SNP rs3093068** CC or CG GG 0.57 (0.17–1.95) 0.37
CFH CT or CC TT 2.80 (1.17–6.70) 0.02
CFH CC CT or TT 31.62 (4.27–234.07) 0.0007
Smoking ≥10 pk-yrs <10 pk-yrs 1.97 (1.12–3.46) 0.02
BMI† 20s ≥25 <25 1.31 (0.61–2.81) 0.50
BMI† 30s ≥25 <25 1.37 (0.70–2.70) 0.36
BMI† 40s ≥25 <25 0.89 (0.49–1.64) 0.71
BMI† 50s ≥25 <25 1.44 (0.76–2.75) 0.27
Overall BMI† ≥25 <25 0.79 (0.43–1.45) 0.45
BMI† 20s (20-25) ≤20 1.09 (0.56–2.10) 0.81
BMI† 30s (20-25) ≤20 1.66 (0.66–4.16) 0.28
BMI† 40s (20-25) ≤20 3.41 (1.05–11.07) 0.04
BMI† 50s (20-25) ≤20 1.46 (0.39–5.52) 0.58
Overall BMI† (20-25) ≤20 2.78 (0.86–9.04) 0.09
BMI† 20s >25 <20 2.87 (0.47–17.5) 0.25
BMI† 30s >25 <20 N/A N/A
BMI† 40s >25 <20 1.00 (0.14–7.10) 1.00
BMI† 50s >25 <20 N/A N/A
Overall BMI† >25 <20 N/A N/A
Diabetes‡ Any type of
diabetes
No diabetes 0.61 (0.27–1.39) 0.24
Single factor conditional logistic regression analyses of risk factors for neovascular age-related macular degeneration using SAS
9.1.  Results from all nine genotyped single nucleotide polymorphisms are shown, including the seven that represent common
genetic variation within CRP (as indicated by the *). The variable pk-yrs means pack-years, which was defined as one pack a
day for one year. The OR is the odds ratio and C.I. is confidence interval. The variable BMI indicates body mass index, which
was calculated by the mean weight in kilograms (excluding pregnancy or lactation) for each decade divided by the square of
the height in meters at age 25 years. Decades shown are 20s, 30s, 40s, and 50s. Diabetes status (both insulin and non-insulin
dependent), was defined by the regular use of medication as reported by the patient for at least six months before the reference
age. N/A means not applicable, the sample size was too small when stratified. Results shown are based on 101 families, using
one pair per family.
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1490for 5 s, and 80 °C for 5 s, then 72 °C for 3 min. The reaction
was then desalted by addition of 6 mg cation exchange Clean
Resin (Sequenom) followed by mixing and centrifugation to
settle the contents of the tube. The extension product was then
spotted onto a 384 well spectroCHIP before being analyzed
in the MALDI-TOF mass spectrometer. Data was collected,
in  real  time,  using  SpectroTYPER  Analyzer  3.3.0.15,
SpectraAQUIRE  3.3.1.1,  and  SpectroCALLER  3.3.0.14
(Sequenom). Additionally, to ensure data quality genotypes
for each subject were also checked manually. For eight SNPs
(rs3093059, rs2794521, rs3093062, rs3091244, rs1417938,
rs1800947,  rs1130864,  and  rs1205)  genotype  data  was
available for 244 individuals. For SNP rs3093068 genotype
data were available for 205 individuals. All individuals were
previously genotyped for CFH Y402.
Statistical  analyses:  The  program  FBAT,  which  tests  for
family-based association, was used to evaluate the effect of
each SNP individually on risk of AMD [24]. Haploview was
used to generate the linkage disequilibrium (LD) plot (Figure
2) among the nine identified SNPs. Linkage disequilibrium
(r2) between each of the nine SNPs is depicted in Figure 2
[30]. The haplotype blocks were constructed by Haploview
using the method proposed by Gabriel et al. [31] Individual
haplotypes were inferred and tested for association with AMD
using FBAT [24]. Conditional logistic regression (CLR; SAS
9.1; SAS Institute Inc, Cary, NC) was performed to identify
factors  associated  with  neovascular  AMD.  Potential  risk
factors of interest, as defined in the previous section, were
evaluated one at a time. For each CRP SNP, the minor allele
(in  unaffected  siblings)  in  both  the  homozygous  and
heterozygous  states  versus  the  common  allele  in  the
homozygous  state  was  examined  in  the  model  (Table  3).
Genotype and allele frequencies for all SNPs identified were
calculated in the affected and separately in unaffected siblings
(Table 4). For this analysis we used one sib pair per family to
eliminate the correlation between siblings. Deviation from
Hardy–Weinberg equilibrium was tested on each SNP using
the χ2 test.
RESULTS
Demographics of participants: The mean age at enrollment
for affected siblings was 71.8 years (range: 49.0–86.5 years).
The mean age at enrollment for the unaffected siblings was
76.1  years  (range:  50.3–93.9  years).  As  reported  in  the
methods section, to ascertain epidemiological exposures, we
calculated the reference age for both affected and unaffected
subjects based on the date of neovascular AMD diagnosis of
the affected sibling. Therefore, the mean age of our unaffected
TABLE 4. GENOTYPE AND ALLELE FREQUENCIES
SNP
Affected siblings
Genotype frequency                                                                        Allele frequency
Homozygous common Heterozygous Homozygous minor Common Minor
rs3093059 TT=89.42 CT=9.62 CC=0.92 T=94.23 C=5.77
rs2794521 AA=55.77 GA=36.54 GG=7.69 A=74.04 G=25.96
rs3093062 GG=99.04 AG=0.96 AA=0.00 G=99.52 A=0.48
rs3091244 CC=36.54 TC=47.12 TT=7.69 C=62.98 T=32.21
AC=5.77 AA=0.96 A=4.81
AT=1.92
rs1417938 CC=45.19 TC=47.12 TT=7.69 C=94.71 T=5.29
rs1800947 GG=89.42 CG=10.58 CC=0.00 G=94.70 C=5.30
rs1130864 AA=43.27 TA=49.04 TT=7.69 A=68.75 T=31.25
rs1205 GG=42.31 AG=44.23 AA=13.46 G=64.42 A=35.58
rs3093068 GG=88.97 CG=10.29 CC=0.74 G=94.71 C=5.29
SNP
Unaffected siblings
Genotype frequenc                                                                          Allele frequency
Homozygous common Heterozygous Homozygous minor Common Minor
rs3093059 TT=85.58 CT=14.42 CC=0.00 T=92.79 C=7.21
rs2794521 AA=55.77 GA=38.46 GG=5.77 A=75.00 G=25.00
rs3093062 GG=99.04 AG=0.96 AA=0.00 G=99.52 A=0.48
rs3091244 CC=31.73 TC=46.15 TT=8.65 C=59.13 T=34.13
AC=8.65 AA=0.00 A=6.73
AT=4.81
rs1417938 CC=40.38 TC=50.00 TT=9.62 C=93.75 T=6.25
rs1800947 GG=88.46 CG=10.58 CC=0.96 G=93.75 C=6.25
rs1130864 AA=41.35 TA=49.04 TT=9.62 A=65.38 T=34.62
rs1205 GG=46.15 AG=45.19 AA=8.65 G=68.75 A=31.25
rs3093068 GG=87.22 CG=12.78 CC=0.00 G=93.56 C=6.44
Genotype and allele frequencies of the nine genotyped single nucleotide polymorphisms of the C-reactive protein gene. Genotype
and allele frequencies are given for the affected sibs and separately for their unaffected siblings.
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1491siblings at the time of their affected siblings’ diagnosis of
neovascular AMD was 72.3 years (range: 41.3–90.9; SD=8.8)
for ascertainment of epidemiological exposures. In addition,
40% of the unaffected siblings were male, and 43% of the
matching affected cases were male.
We  sequenced  92.3%  of  the  CRP  gene  which
encompasses 961 bp from the first ATG to the stop codon
(TGA)  according  to  Ensembl.  Additionally,  to  ensure  we
captured the previously reported CRP common variation, we
sequenced a 925 bp region of the 5′UTR and 1,202 bp region
of the 3′UTR. No new variation was uncovered within any of
the CRP fragments analyzed. Aside from the seven SNPs
representing common variation, a previously reported SNP
(rs3093062) was identified in the promoter region (Table 2,
Table  3,  and  Figure  1)  [16-18,21].  We  did  not  find  a
statistically significant association between any of the nine
CRP  SNPs  representing  common  and  risk  of  neovascular
AMD using the family-based association test (Table 2), single
factor CLR (p≥0.2; Table 3) or McNemar’s test (data not
shown). When we controlled for smoking exposure (≥ 10
package years or < 10 package years), BMI by decade and
over a lifetime, as well as CFH genotype, none of the minor
Figure  2.  Linkage  Disequilibrium  of  Single  Nucleotide
Polymorphisms (SNPs) along the 1q25 region encompassing the
CRP gene and illustrating the 1 distinct haplotype block, defined by
the confidence intervals, an algorithm proposed by Gabriel et al.
[31] using HAPLOVIEW. The linkage disequilibrium (r2) between
any two SNPs is listed in the cross cell. Asterisk means the darker
the color indicates the higher the linkage disequilibrium between any
two SNPs. Please note that SNP rs3091244 consists of three alleles;
two minor alleles A and T are combined into one minor allele due to
the limitation of the program which only allows for dichotomous
SNPs. SNP rs3093068 was genotyped on 205 subjects, whereas the
other eight SNPs were genotyped on 244 subjects.
alleles  demonstrated  any  significant  association  with
neovascular AMD either (data not shown). Though presence
of diabetes and a BMI greater than 25 were both higher in
unaffected siblings (36.2% and 42.9% respectively) when
compared to affected siblings (12.9% and 20.7% respectively)
both single factor CLR and the McNemar’s test showed no
significant association between BMI and neovascular AMD,
or between diabetes status and neovascular AMD (Table 3).
No  significant  deviations  from  Hardy–Weinberg
equilibrium (HWE) for any of the genotypes studied in CRP
was  observed  in  either  the  affected  or  unaffected  sets  of
siblings suggesting no contamination of our data set (Table
4). When testing for significant departures from HWE, we
used  one  degree  of  freedom  for  the  biallelic  SNPs
(rs3093059,  rs279452,  rs3093062,  rs1417938,  rs1800947,
rs1130864, and rs1205) and three degrees of freedom for the
SNP rs3091244, which has three alleles.
Six  SNPs  (rs3091244,  rs1417938,  rs1800947,
rs1130864, rs1205, and rs3093068) constituted a haplotype
block of which only rs1130864 and rs1417938 were in high
LD (r2=0.94) (Figure 2) [30]. SNP rs3093068 was in LD but
less so with rs3093059 (r2=0.83), which was not part of the
haplotype block. SNPs which made up the haplotype block
comprised  six  different  haplotypes  with  ≥  5%  frequency
(Table  5,Table  6,Table  7).  Haplotype  analysis  using  the
family-based  association  approach  showed  no  significant
association  between  any  of  the  six  haplotypes  and  AMD
(Table 5 and Table 7). In an effort to replicate the findings by
the  Rotterdam  Study  [22]  we  also  conducted  haplotype
analysis  on  the  three  SNPs  (rs1130864,  rs1205,  and
rs3093068)  analyzed  in  that  study  that  defined  common
variation and were part of the same haplotype block (Figure
2  and  Table  7).  Although  the  frequencies  for  the  four
haplotypes in our population (h1: 0.33, h2:0.32, h3:0.30, and
h4:0.06) were similar to those in the Rotterdam population
(h1: 0.33, h2:0.32, h3:0.28, and h4:0.05) we did not find a
statistically significant association with AMD risk (Table 6).
When  we  stratified  the  haplotypes  according  to  CFH
genotype, we were only left with a handful of sib pairs in each
subgroup (6–12) and were thus relatively underpowered to
detect an association in this manner.
DISCUSSION
In  summary,  no  statistically  significant  association  was
detected  between  any  of  the  nine  SNPs  identified  in  the
CRP gene and neovascular AMD when considering disease
status alone or with stratification by smoking exposure, BMI,
or CFH genotype. Haplotype analysis resulted in the same
findings as single factor SNP analysis, demonstrating that
there was no association between the CRP gene and risk of
neovascular  AMD.  Our  findings  are  supported  by  similar
results from the Physician’s Health Study that showed no
association between common variation in the CRP gene and
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1492risk  of  AMD  after  controlling  for  CFH  genotype  [23].
Additionally,  direct  sequencing  of  CRP  in  our  extremely
discordant sib pair population uncovered no new variation.
These findings taken together could suggest that if elevated
circulating levels of CRP are associated with AMD, it is likely
not due to genetic variation within CRP but likely variation in
some  other  gene  or  epidemiological  risk  factor.  Further
supporting this hypothesis is that in a study of over 3,000
subjects  [32]  variation  in  circulating  CRP  levels  was
accounted for by phenotypic factors (such as a high BMI >
25)  rather  than  CRP  genotype  (26%  versus  1.4%).
Nevertheless, analysis of three common variants in the 3′-
UTR within CRP, on a prospective study population from the
Netherlands  [22]  showed  that  haplotypes  associated  with
higher circulating CRP levels are protective in individuals
who are CFH Y402, and these same haplotypes can confer
increased risk on AMD in individuals who are CFH 402H. It
is important to note that in the Rotterdam study, the haplotypes
studied were not directly associated with AMD risk [22].
Although our population of neovascular AMD (n=116) was
slightly higher than that of the Rotterdam study (n=78), which
did not differentiate between the advanced subtypes of AMD,
it  may  be  that  our  results  are  inconclusive  as  we  were
relatively  underpowered  when  we  stratified  subjects
according to CFH genotype. Since subjects in both of these
studies are Caucasian, it could also be that if variation in
CRP  increases  susceptibility  to  advanced  AMD,  it  may
predispose to only the atrophic subtype. Another possibility
is that CRP variants may have a small or modest influence on
AMD risk, or there may exist multiple susceptibility genes for
AMD that are not necessarily expressed in every patient.
To assess the power of the current study, we used a power
calculation  specifically  designed  for  discordant  sib  pair
studies, given the genetic parameters. We made the following
reasonable assumptions that we felt reflected our knowledge
on the CRP gene: 1) the CRP gene is a weak AMD risk factor
with relative risk from 1.5 to 3; 2) the prevalence of AMD in
people older than 60 is 0.2 [32]; 3) the significance level is
TABLE 5. HAPLOTYPE ANALYSIS
Order rs3091244 rs1417938 rs1800947 rs1130864 rs1205 rs3093068
Number of
Informative
Families Frequency p value*
h1 C A G C G G 31.1 0.335 0.9214
h2 T T G T G G 31.6 0.272 0.9233
h3 C A G C A G 31.6 0.254 0.494
Haplotype analysis of the C-reactive protein gene using the program FBAT. The single nucleotide polymorphisms used in this
analysis  are based on the haplotype block produced by Haploview and shown in Figure 2. Haplotypes shown are only those that
occurred at a frequency of greater than 5% in our population. The p-values given are based on 100,000 permutations.
TABLE 6. FULL HAPLOTYPE ANALYSIS
Order rs3091244 rs1417938 rs1800947 rs1130864 rs1205 rs3093068 Frequency
h1 C A G C G G 0.335
h2 T T G T G G 0.272
h3 C A G C A G 0.254
h4 A A G C G C 0.254
h5 C A C C A G 0.054
h6 C T G C A G 0.051
h7 T A G T G G 0.004
h8 A A G C A C 0.003
h9 C A G T G G 0.003
h10 T T G C G G 0.003
h11 C T G T G G 0.003
h12 T A G C G C 0.003
h13 A A C C A G 0.003
h14 T A C C A G 0.003
h15 T T C T A G 0.003
h16 T T G T A G 0.001
All haplotypes produced by the FBAT analysis of the C-reactive protein gene. The frequency of these haplotypes in our
population is shown. Please note that many of these haplotypes occurred infrequently in our population.
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14930.01,  which  considers  multiple  testing  correction  without
overcorrecting; and 4) the genetic proportion (the percentage
of cases with AMD that is due to disease genotype) ranges
from 0.3 to 0.6. The current data contains 104 sib pairs for the
majority of the SNPs analyzed. Both dominant and recessive
genetic models are considered. The power of the study ranges
from 7% to 78% under a dominant model and ranges from 4%
to  60%  under  a  recessive  model.  In  both  dominant  and
recessive models, the power is low when the relative risk and
genetic proportion are low; the power increases when relative
risk and genetic proportion increase. When the relative risk is
1.5, the power is very low, around 5%, there is little or no
power  to  detect  any  association;  when  the  relative  risk
approaches 3 and the genetic proportion is close to 50% to
60%,  the  study  possesses  a  power  >  70%  to  detect  the
association.
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